351 related articles for article (PubMed ID: 32621174)
21. Impact of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Updates on HER2 Assessment in Breast Cancer With Equivocal HER2 Immunohistochemistry Results With Focus on Cases With
Hoda RS; Brogi E; Xu J; Ventura K; Ross DS; Dang C; Robson M; Norton L; Morrow M; Wen HY
Arch Pathol Lab Med; 2020 May; 144(5):597-601. PubMed ID: 31647316
[TBL] [Abstract][Full Text] [Related]
22. HER2 gene assessment in liquid biopsy of gastric and esophagogastric junction cancer patients qualified for surgery.
Grenda A; Wojas-Krawczyk K; Skoczylas T; Krawczyk P; Sierocińska-Sawa J; Wallner G; Milanowski J
BMC Gastroenterol; 2020 Nov; 20(1):382. PubMed ID: 33198632
[TBL] [Abstract][Full Text] [Related]
23. ERBB2 amplification status in 67 salivary duct carcinomas assessed by immunohistochemistry, fluorescence in situ hybridization, and targeted exome sequencing.
Ferguson DC; Momeni Boroujeni A; Zheng T; Mohanty AS; Ho AL; Arcila ME; Ross DS; Dogan S
Mod Pathol; 2022 Jul; 35(7):895-902. PubMed ID: 34963694
[TBL] [Abstract][Full Text] [Related]
24. Gene protein detection platform--a comparison of a new human epidermal growth factor receptor 2 assay with conventional immunohistochemistry and fluorescence in situ hybridization platforms.
Stålhammar G; Farrajota P; Olsson A; Silva C; Hartman J; Elmberger G
Ann Diagn Pathol; 2015 Aug; 19(4):203-10. PubMed ID: 25921313
[TBL] [Abstract][Full Text] [Related]
25. Clinical array-based karyotyping of breast cancer with equivocal HER2 status resolves gene copy number and reveals chromosome 17 complexity.
Gunn S; Yeh IT; Lytvak I; Tirtorahardjo B; Dzidic N; Zadeh S; Kim J; McCaskill C; Lim L; Gorre M; Mohammed M
BMC Cancer; 2010 Jul; 10():396. PubMed ID: 20667129
[TBL] [Abstract][Full Text] [Related]
26. Assessment of HER2 status in invasive breast cancers with increased centromere 17 copy number.
Jang MH; Kim EJ; Kim HJ; Chung YR; Park SY
Breast Cancer Res Treat; 2015 Aug; 153(1):67-77. PubMed ID: 26223814
[TBL] [Abstract][Full Text] [Related]
27. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
[TBL] [Abstract][Full Text] [Related]
28. Detection of HER2 amplification in formalin-fixed paraffin-embedded breast carcinoma tissue with digital PCR using two TFF3 sequences as internal reference.
Yu R; Xuan W; Zhou L; Luo Y; Liu X; Xiong P; Ren X
Exp Mol Pathol; 2018 Jun; 104(3):235-238. PubMed ID: 29715436
[TBL] [Abstract][Full Text] [Related]
29. Estimating copy number using next-generation sequencing to determine ERBB2 amplification status.
Nakamura K; Aimono E; Oba J; Hayashi H; Tanishima S; Hayashida T; Chiyoda T; Kosaka T; Hishida T; Kawakubo H; Kitago M; Okabayashi K; Funakoshi T; Okita H; Ikeda S; Takaishi H; Nishihara H
Med Oncol; 2021 Mar; 38(4):36. PubMed ID: 33710417
[TBL] [Abstract][Full Text] [Related]
30. Comparison of an amplicon-based large panel next generation sequencing (NGS) assay with conventional testing methods for MET and HER2 amplification in lung and breast cancers.
Tay TKY; Tan GS; Lee SH; Sam XX; Lim TH; Ng JWK; Tan DSW; Lim TKH
Pathology; 2024 Apr; 56(3):325-333. PubMed ID: 38195375
[TBL] [Abstract][Full Text] [Related]
31. Droplet digital PCR measurement of HER2 copy number alteration in formalin-fixed paraffin-embedded breast carcinoma tissue.
Belgrader P; Tanner SC; Regan JF; Koehler R; Hindson BJ; Brown AS
Clin Chem; 2013 Jun; 59(6):991-4. PubMed ID: 23358413
[TBL] [Abstract][Full Text] [Related]
32. Quantitative RT-PCR assay of HER2 mRNA expression in formalin-fixed and paraffin-embedded breast cancer tissues.
Park S; Wang HY; Kim S; Ahn S; Lee D; Cho Y; Park KH; Jung D; Kim SI; Lee H
Int J Clin Exp Pathol; 2014; 7(10):6752-9. PubMed ID: 25400755
[TBL] [Abstract][Full Text] [Related]
33. HER2 Gene Amplification by Fluorescence In Situ Hybridization (FISH) Compared With Immunohistochemistry (IHC) in 122 Equivocal Gastric Cancer Cases.
Liu X; Wang X; Wang B; Ren G; Ding W
Appl Immunohistochem Mol Morphol; 2016 Aug; 24(7):459-64. PubMed ID: 26317310
[TBL] [Abstract][Full Text] [Related]
34. Updated 2013 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) guideline recommendations for human epidermal growth factor receptor 2 (HER2) fluorescent in situ hybridization (FISH) testing increase HER2 positive and HER2 equivocal breast cancer cases; retrospective study of HER2 FISH results of 836 invasive breast cancers.
Singh K; Tantravahi U; Lomme MM; Pasquariello T; Steinhoff M; Sung CJ
Breast Cancer Res Treat; 2016 Jun; 157(3):405-11. PubMed ID: 27180259
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of HER2 Gene Status in Breast Cancer Samples with Indeterminate Fluorescence in Situ Hybridization by Quantitative Real-Time PCR.
Koudelakova V; Berkovcova J; Trojanec R; Vrbkova J; Radova L; Ehrmann J; Kolar Z; Melichar B; Hajduch M
J Mol Diagn; 2015 Jul; 17(4):446-55. PubMed ID: 25956448
[TBL] [Abstract][Full Text] [Related]
36. [Analysis of HER2 gene status in breast cancer with HER2 protein overexpression].
Zeng X; Liang ZY; Wu SF; Zhou WX; Gao J; Liu TH
Zhonghua Bing Li Xue Za Zhi; 2006 Oct; 35(10):584-8. PubMed ID: 17134563
[TBL] [Abstract][Full Text] [Related]
37. Human epidermal growth factor receptor 2 expression in breast cancer: correlation with clinical pathological features.
Ning SF; Li JL; Luo CP; Wei CH; Lu YK; Liu HZ; Wei WE; Zhang LT
Int J Clin Exp Pathol; 2014; 7(12):8740-7. PubMed ID: 25674240
[TBL] [Abstract][Full Text] [Related]
38. The updated 2018 American Society of Clinical Oncology/College of American Pathologists guideline on human epidermal growth factor receptor 2 interpretation in breast cancer: comparison with previous guidelines and clinical significance of the proposed in situ hybridization groups.
Woo JW; Lee K; Chung YR; Jang MH; Ahn S; Park SY
Hum Pathol; 2020 Apr; 98():10-21. PubMed ID: 32027910
[TBL] [Abstract][Full Text] [Related]
39. HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry.
Morsberger L; Pallavajjala A; Long P; Hardy M; Park R; Parish R; Nozari A; Zou YS
Cancer Cell Int; 2022 Nov; 22(1):350. PubMed ID: 36376842
[TBL] [Abstract][Full Text] [Related]
40. Clinical role of HER2 gene amplification and chromosome 17: a study on 154 IHC-equivocal cases of invasive breast carcinoma patients.
Afzal M; Amir M; Hassan MJ; Hussain MS; Aziz MN; Murad S; Murtaza I; Anees M; Sultan A
Tumour Biol; 2016 Jul; 37(7):8665-72. PubMed ID: 26738861
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
